Phase II study of flavopiridol in patients with advanced colorectal cancer.

BACKGROUND Flavopiridol, a synthetic flavone that inhibits cell cycle progression, has demonstrated activity in colon cancer in xenografts and in a phase I trial. We evaluated flavopiridol in a phase II trial in patients with previously untreated advanced colorectal cancer (ACRC). PATIENTS AND METHODS Twenty chemotherapy-naïve patients with ACRC received flavopiridol at a dose of 50 mg/m(2)/day via a 72-h continuous infusion every 14 days. Response was assessed by computed tomography or magnetic resonance imaging every 8 weeks. RESULTS Twenty patients were enrolled; 19 were evaluable for toxicity and 18 for response. There were no objective responses. Five patients had stable disease lasting a median of 7 weeks. The median time to progression was 8 weeks. Median survival was 65 weeks. The principal grade 3/4 toxicities were diarrhea, fatigue and hyperglycemia, occurring in 21%, 11% and 11% of patients, respectively. Other common toxicities included anemia, anorexia and nausea/vomiting. CONCLUSIONS Flavopiridol in this dose and schedule does not have single-agent activity in patients with ACRC. Recent preclinical data suggest that flavopiridol enhances apoptosis when combined with chemotherapy. Trials that evaluate flavopiridol in combination with active cytotoxic drugs should help to define the role of this novel agent in ACRC.

[1]  A Messori,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[2]  S. Kaufmann,et al.  Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. , 1996, Cancer research.

[3]  J. Gabrilove,et al.  The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. , 1997, Blood.

[4]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[5]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[6]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[7]  B. Franza,et al.  cdc2 phosphorylation is required for its interaction with cyclin. , 1991, The EMBO journal.

[8]  J. Verweij,et al.  Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  E. Sausville,et al.  Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. , 1993, Biochemical pharmacology.

[10]  W. Stadler,et al.  In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer , 1999, Cancer Chemotherapy and Pharmacology.

[11]  E. Sausville,et al.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. , 1998, The Journal of clinical investigation.

[12]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[13]  Jean,et al.  Cyclin B targets p34cdc2 for tyrosine phosphorylation. , 1991, The EMBO journal.

[14]  E. Nigg,et al.  Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: identification of major phosphorylation sites. , 1991, The EMBO journal.

[15]  E. Sausville,et al.  Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. , 1998, Blood.

[16]  E. Sausville,et al.  Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.

[17]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[18]  E. Sausville,et al.  Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. , 1998, Blood.

[19]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[20]  J. Labbé,et al.  Dephosphorylation of cdc2 on threonine 161 is required for cdc2 kinase inactivation and normal anaphase. , 1992, The EMBO journal.

[21]  P. Nurse,et al.  Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. , 1991, The EMBO journal.

[22]  S. Kaufmann,et al.  Antineoplastic Agents: the Importance of Sequence of Administration' , 2022 .

[23]  E. Sausville,et al.  Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. , 1996, International journal of oncology.

[24]  S. Steinberg,et al.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Gonen,et al.  Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.